187P Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer
Luca Licata(Vita-Salute San Raffaele University), Giampaolo Bianchini(Vita-Salute San Raffaele University), Giuseppe Curigliano(European Institute of Oncology), Fabio Puglisi(University of Udine), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Lajos Pusztai(Yale University), R Collins(South Carolina Oncology Associates), Oluchi Oke(The University of Texas MD Anderson Cancer Center), Filippo Montemurro(Roche (Switzerland)), Lorenzo Sica(IRCCS Ospedale San Raffaele), Mariana Chávez‐MacGregor(The University of Texas MD Anderson Cancer Center), Lorenzo Gerratana(National Cancer Institute), Mario Giuliano(Regione Campania), Giulia Viale(Istituti di Ricovero e Cura a Carattere Scientifico), Lucia Del Mastro(Ospedale Policlinico San Martino), Alessia Rognone(IRCCS Ospedale San Raffaele), Antonio Giordano(Harvard University), Carmen Criscitiello(University of Milan), Sara Giordano(Harvard University), Julia Foldi(University of Pittsburgh)
Cited by 0
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k